MARK4 plays a role in the development of DM and cancer among other neurodegenerative diseases; linagliptin is a potential inhibitor of MARK4 and may act as a molecule against MARK4-mediated neurodegenerative diseases [45]. This evidence concerns the gene MARK4 and diabetes mellitus.